Definium Therapeutics has priced an upsized underwritten public offering of 20.59 million common shares at $34.00 per share, expected to generate approximately $700 million in gross proceeds before underwriting discounts and offering expenses. The company originally targeted a capital raise of $500 million. Underwriters have a 30-day option to purchase up to an additional 3.09 million shares at the same price. Proceeds will fund research and development, including potential commercialization activities for DT120 ODT if approved, as well as working capital and general corporate purposes. The offering is expected to close around June 25, 2026, subject to customary closing conditions, and no distribution will occur in Canada or to Canadian residents.
Definium Therapeutics, Inc.Priced upsized public offering at $34 per share, diluting existing shareholders.